Literature DB >> 27197175

Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer.

Domenico Albino1, Gianluca Civenni1, Cecilia Dallavalle1, Martina Roos2, Hartmut Jahns2, Laura Curti1, Simona Rossi1, Sandra Pinton1, Gioacchino D'Ambrosio3, Fausto Sessa4, Jonathan Hall2, Carlo V Catapano5, Giuseppina M Carbone6.   

Abstract

Although cancer stem-like cells (CSC) are thought to be the most tumorigenic, metastatic, and therapy-resistant cell subpopulation within human tumors, current therapies target bulk tumor cells while tending to spare CSC. In seeking to understand mechanisms needed to acquire and maintain a CSC phenotype in prostate cancer, we investigated connections between the ETS transcription factor ESE3/EHF, the Lin28/let-7 microRNA axis, and the CSC subpopulation in this malignancy. In normal cells, we found that ESE3/EHF bound and repressed promoters for the Lin28A and Lin28B genes while activating transcription and maturation of the let-7 microRNAs. In cancer cells, reduced expression of ESE3/EHF upregulated Lin28A and Lin28B and downregulated the let-7 microRNAs. Notably, we found that deregulation of the Lin28/let-7 axis with reduced production of let-7 microRNAs was critical for cell transformation and expansion of prostate CSC. Moreover, targeting Lin28A/Lin28B in cell lines and tumor xenografts mimicked the effects of ESE3/EHF and restrained tumor-initiating and self-renewal properties of prostate CSC both in vitro and in vivo These results establish that tight control by ESE3/EHF over the Lin28/let-7 axis is a critical barrier to malignant transformation, and they also suggest new strategies to antagonize CSC in human prostate cancer for therapeutic purposes. Cancer Res; 76(12); 3629-43. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197175     DOI: 10.1158/0008-5472.CAN-15-2665

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma.

Authors:  Li Chen; Moli Huang; Jasmine Plummer; Jian Pan; Yan Yi Jiang; Qian Yang; Tiago Chedraoui Silva; Nicole Gull; Stephanie Chen; Ling Wen Ding; Omer An; Henry Yang; Yulan Cheng; Jonathan W Said; Ngan Doan; Winand Nm Dinjens; Kevin M Waters; Richard Tuli; Simon A Gayther; Samuel J Klempner; Benjamin P Berman; Stephen J Meltzer; De-Chen Lin; H Phillip Koeffler
Journal:  Gut       Date:  2019-08-13       Impact factor: 23.059

2.  ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.

Authors:  Tiansuo Zhao; Wenna Jiang; Xiuchao Wang; Hongwei Wang; Chen Zheng; Yang Li; Yan Sun; Chongbiao Huang; Zhi-Bo Han; Shengyu Yang; Zhiliang Jia; Keping Xie; He Ren; Jihui Hao
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

Review 3.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

4.  Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells.

Authors:  Davide Genini; Lara Brambilla; Erik Laurini; Jessica Merulla; Gianluca Civenni; Shusil Pandit; Rocco D'Antuono; Laurent Perez; David E Levy; Sabrina Pricl; Giuseppina M Carbone; Carlo V Catapano
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

5.  Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo.

Authors:  Christian Berk; Gianluca Civenni; Yuluan Wang; Christian Steuer; Carlo V Catapano; Jonathan Hall
Journal:  Nucleic Acid Ther       Date:  2020-04-20       Impact factor: 5.486

Review 6.  MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.

Authors:  Bethany Smith; Priyanka Agarwal; Neil A Bhowmick
Journal:  Endocr Relat Cancer       Date:  2017-03-13       Impact factor: 5.678

Review 7.  The LIN28/let-7 Pathway in Cancer.

Authors:  Julien Balzeau; Miriam R Menezes; Siyu Cao; John P Hagan
Journal:  Front Genet       Date:  2017-03-28       Impact factor: 4.599

8.  The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.

Authors:  Domenico Albino; Gianluca Civenni; Simona Rossi; Abhishek Mitra; Carlo V Catapano; Giuseppina M Carbone
Journal:  Oncotarget       Date:  2016-11-22

9.  ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.

Authors:  Tianxing Zhou; Jing Liu; Yongjie Xie; Shuai Yuan; Yu Guo; Weiwei Bai; Kaili Zhao; Wenna Jiang; Hongwei Wang; Haotian Wang; Tiansuo Zhao; Chongbiao Huang; Song Gao; Xiuchao Wang; Shengyu Yang; Jihui Hao
Journal:  Gut       Date:  2021-03-05       Impact factor: 31.793

10.  Establishment and Characterization of a Human Small Cell Osteosarcoma Cancer Stem Cell Line: A New Possible In Vitro Model for Discovering Small Cell Osteosarcoma Biology.

Authors:  Gaia Palmini; Roberto Zonefrati; Cecilia Romagnoli; Alessandra Aldinucci; Carmelo Mavilia; Gigliola Leoncini; Alessandro Franchi; Rodolfo Capanna; Maria Luisa Brandi
Journal:  Stem Cells Int       Date:  2016-08-29       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.